Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Lakshmi Nayak, Chetan Bettegowda, Florian Scherer, Norbert Galldiks, Manmeet Ahluwalia, Alexander Baraniskin, Louisa von Baumgarten, Jacoline E C Bromberg, Andrés J M Ferreri, Christian Grommes, Khê Hoang-Xuan, Julia Kühn, James L Rubenstein, Roberta Rudà, Michael Weller, Susan M Chang, Martin J van den Bent, Patrick Y Wen, Riccardo Soffietti
BACKGROUND: The utility of liquid biopsies is well documented in several extracranial and intracranial (brain/leptomeningeal metastases, gliomas) tumors. METHODS: The RANO (Response Assessment in Neuro-Oncology) group has set up a multidisciplinary Task Force to critically review the role of blood and CSF-liquid biopsy in central nervous system lymphomas, with a main focus on primary central nervous system lymphomas (PCNSL). RESULTS: Several clinical applications are suggested: diagnosis of PCNSL in critical settings (elderly or frail patients, deep locations, steroids responsiveness), definition of minimal residual disease, early indication of tumor response or relapse following treatments and prediction of outcome...
April 10, 2024: Neuro-oncology
#2
JOURNAL ARTICLE
Jochem K H Spoor, Marike Donders-Kamphuis, Wencke S Veenstra, Sarah A van Dijk, Clemens M F Dirven, Peter A E Sillevis Smitt, Martin J van den Bent, Sieger Leenstra, Djaina D Satoer
BACKGROUND: The health-related quality of life (HRQoL) and cognition are important indicators for the quality of survival in patients with high-grade glioma (HGG). However, data on long-term survivors and their caregivers are scarce. We aim to investigate the interaction between cognition and HRQoL in long-term survivors, their caregivers' evaluations, and the effect on caregiver strain and burden. METHODS: 21 long-term HGG (8 WHO grade III and 13 WHO grade IV) survivors (survival ≥ 5 years) and 15 caregivers were included...
April 3, 2024: Acta Neurochirurgica
#3
Santoesha A Ghisai, Levi van Hijfte, Wies R Vallentgoed, C Mircea S Tesileanu, Iris de Heer, Johan M Kros, Marc Sanson, Thierry Gorlia, Wolfgang Wick, Michael A Vogelbaum, Alba A Brandes, Enrico Franceschi, Paul M Clement, Anna K Nowak, Vassilis Golfinopoulos, Martin J van den Bent, Pim J French, Youri Hoogstrate
Accurate grading of IDH-mutant gliomas defines patient prognosis and guides the treatment path. Histological grading is however difficult and, apart from CDKN2A/B homozygous deletions in IDH-mutant astrocytomas, there are no other objective molecular markers used for grading. Experimental Design: RNA-sequencing was conducted on primary IDH-mutant astrocytomas (n=138) included in the prospective CATNON trial, which was performed to assess the prognostic effect of adjuvant and concurrent temozolomide. We integrated the RNA sequencing data with matched DNA-methylation and NGS data...
March 20, 2024: bioRxiv
#4
JOURNAL ARTICLE
Ilanah J Pruis, Pieter Jan van Doormaal, Rutger K Balvers, Martin J van den Bent, Anita A Harteveld, Linda C de Jong, Mark W Konijnenberg, Marcel Segbers, Roelf Valkema, Frederik A Verburg, Marion Smits, Sophie E M Veldhuijzen van Zanten
BACKGROUND: The aim of this study was to provide quantitative evidence for the potential of PSMA-targeting radioligand therapy (RLT) as treatment approach for malignant brain tumours, and to explore whether tumour uptake could be enhanced by super-selective intra-arterial (ssIA)-administration. METHODS: Ten patients (n = 5 high-grade glioma, n = 5 brain metastasis) received 1.5 MBq/kg [68 Ga]Ga-PSMA-11 intravenously and, within 7 days, intra-arterially (i...
March 21, 2024: EBioMedicine
#5
JOURNAL ARTICLE
Florentine E F Timmer, Bart Geboers, Alette H Ruarus, Laurien G P H Vroomen, Evelien A C Schouten, Susan van der Lei, Danielle J W Vos, Madelon Dijkstra, Hannah H Schulz, Joyce Bakker, Bente A T van den Bemd, Petrousjka M van den Tol, Robbert S Puijk, Birgit I Lissenberg-Witte, Tanja D de Gruijl, Jan J J de Vries, Frank J Lagerwaard, Hester J Scheffer, Anna M E Bruynzeel, Martijn R Meijerink
BACKGROUND: Pancreatic ductal adenocarcinoma is an aggressive disease with a dismal prognosis. Stage III locally advanced pancreatic cancer is considered unresectable and current palliative chemotherapy regimens only modestly improve survival. Guidelines suggest chemoradiation or stereotactic ablative body radiotherapy (SABR) could be beneficial in certain circumstances. Other local treatments such as irreversible electroporation could enhance patient outcomes by extending survival while preserving quality of life...
March 18, 2024: Lancet. Gastroenterology & Hepatology
#6
JOURNAL ARTICLE
Ann Schirin Mirsanaye, Saskia Hoffmann, Melanie Weisser, Andreas Mund, Blanca Lopez Mendez, Dimitris Typas, Johannes van den Boom, Bente Benedict, Ivo A Hendriks, Michael Lund Nielsen, Hemmo Meyer, Julien P Duxin, Guillermo Montoya, Niels Mailand
The hexameric AAA+ ATPase p97/VCP functions as an essential mediator of ubiquitin-dependent cellular processes, extracting ubiquitylated proteins from macromolecular complexes or membranes by catalyzing their unfolding. p97 is directed to ubiquitylated client proteins via multiple cofactors, most of which interact with the p97 N-domain. Here, we discover that FAM104A, a protein of unknown function also named VCF1 (VCP/p97 nuclear Cofactor Family member 1), acts as a p97 cofactor in human cells. Detailed structure-function studies reveal that VCF1 directly binds p97 via a conserved α-helical motif that recognizes the p97 N-domain with unusually high affinity, exceeding that of other cofactors...
March 19, 2024: Nature Communications
#7
JOURNAL ARTICLE
Patrick Roth, Thierry Gorlia, Jaap C Reijneveld, Filip de Vos, Ahmed Idbaih, Jean-Sébastien Frenel, Emilie Le Rhun, Juan Manuel Sepulveda, James Perry, G Laura Masucci, Pierre Freres, Hal Hirte, Clemens Seidel, Annemiek Walenkamp, Slavka Lukacova, Paul Meijnders, Andre Blais, Francois Ducray, Vincent Verschaeve, Garth Nicholas, Carmen Balana, Daniela A Bota, Matthias Preusser, Sarah Nuyens, Fréderic Dhermain, Martin van den Bent, Chris J O'Callaghan, Maureen Vanlancker, Warren Mason, Michael Weller
BACKGROUND: Standard treatment for patients with newly diagnosed glioblastoma includes surgery, radiotherapy (RT) and temozolomide (TMZ) chemotherapy (TMZ/RT→TMZ). The proteasome has long been considered a promising therapeutic target because of its role as a central biological hub in tumor cells. Marizomib is a novel pan-proteasome inhibitor that crosses the blood brain barrier. METHODS: EORTC 1709/CCTG CE.8 was a multicenter, randomized, controlled, open label phase 3 superiority trial...
March 19, 2024: Neuro-oncology
#8
JOURNAL ARTICLE
Laure Gossec, Andreas Kerschbaumer, Ricardo J O Ferreira, Daniel Aletaha, Xenofon Baraliakos, Heidi Bertheussen, Wolf-Henning Boehncke, Bente Appel Esbensen, Iain B McInnes, Dennis McGonagle, Kevin L Winthrop, Andra Balanescu, Peter V Balint, Gerd R Burmester, Juan D Cañete, Pascal Claudepierre, Lihi Eder, Merete Lund Hetland, Annamaria Iagnocco, Lars Erik Kristensen, Rik Lories, Rubén Queiro, Daniele Mauro, Helena Marzo-Ortega, Philip J Mease, Peter Nash, Wendy Wagenaar, Laura Savage, Georg Schett, Stephanie J W Shoop-Worrall, Yoshiya Tanaka, Filip E Van den Bosch, Annette van der Helm-van Mil, Alen Zabotti, Désirée van der Heijde, Josef S Smolen
OBJECTIVE: New modes of action and more data on the efficacy and safety of existing drugs in psoriatic arthritis (PsA) required an update of the EULAR 2019 recommendations for the pharmacological treatment of PsA. METHODS: Following EULAR standardised operating procedures, the process included a systematic literature review and a consensus meeting of 36 international experts in April 2023. Levels of evidence and grades of recommendations were determined. RESULTS: The updated recommendations comprise 7 overarching principles and 11 recommendations, and provide a treatment strategy for pharmacological therapies...
March 18, 2024: Annals of the Rheumatic Diseases
#9
JOURNAL ARTICLE
Bente A van den Berge, Feikje Groenhof, Paul M N Werker, Dominic Furniss, Rachel Kuo, Edwin R van den Heuvel, Dieuwke C Broekstra
Previous studies suggest that Dupuytren's disease is associated with increased mortality, but most studies failed to account for important confounders. In this population-based cohort study, general practitioners' (GP) data were linked to Statistics Netherlands to register all-cause and disease-specific mortality. Patients with Dupuytren's disease were identified using the corresponding diagnosis code and assessing free-text fields from GP consultations. Multiple imputations were performed to estimate missing values of covariates, followed by 1:7 propensity score matching to balance cases with controls on confounding factors...
March 15, 2024: Journal of Hand Surgery, European Volume
#10
JOURNAL ARTICLE
Isabel Arrillaga-Romany, Andrew Lassman, Susan L McGovern, Sabine Mueller, Burt Nabors, Martin van den Bent, Michael Vogelbaum, Joshua E Allen, Allen S Melemed, Rohinton S Tarapore, Patrick Y Wen, Timothy Cloughesy
BACKGROUND: H3 K27M-mutant diffuse glioma primarily affects children and young adults, is associated with a poor prognosis, and no effective systemic therapy is currently available. ONC201 (dordaviprone) has previously demonstrated efficacy in patients with recurrent disease. This phase 3 trial evaluates ONC201 in patients with newly diagnosed H3 K27M-mutant glioma. METHODS: ACTION (NCT05580562) is a randomized, double-blind, placebo-controlled, parallel-group, international Phase 3 study of ONC201 in newly diagnosed H3 K27M-mutant diffuse glioma...
March 6, 2024: Neuro-oncology
#11
MULTICENTER STUDY
Aditya Rastogi, Gianluca Brugnara, Martha Foltyn-Dumitru, Mustafa Ahmed Mahmutoglu, Chandrakanth J Preetha, Erich Kobler, Irada Pflüger, Marianne Schell, Katerina Deike-Hofmann, Tobias Kessler, Martin J van den Bent, Ahmed Idbaih, Michael Platten, Alba A Brandes, Burt Nabors, Roger Stupp, Denise Bernhardt, Jürgen Debus, Amir Abdollahi, Thierry Gorlia, Jörg-Christian Tonn, Michael Weller, Klaus H Maier-Hein, Alexander Radbruch, Wolfgang Wick, Martin Bendszus, Hagen Meredig, Felix T Kurz, Philipp Vollmuth
BACKGROUND: The extended acquisition times required for MRI limit its availability in resource-constrained settings. Consequently, accelerating MRI by undersampling k-space data, which is necessary to reconstruct an image, has been a long-standing but important challenge. We aimed to develop a deep convolutional neural network (dCNN) optimisation method for MRI reconstruction and to reduce scan times and evaluate its effect on image quality and accuracy of oncological imaging biomarkers...
March 2024: Lancet Oncology
#12
JOURNAL ARTICLE
Emilie Le Rhun, Patrick Devos, Katharina Seystahl, Joost L M Jongen, Dorothee Gramatzki, Patrick Roth, Martin J Van Den Bent, Luca Regli, Dieta Brandsma, Michael Weller
BACKGROUND AND OBJECTIVES: Hydrocephalus is a common radiologic sign in patients with leptomeningeal metastasis (LM) from solid tumors which can be assessed using the Evans index (EI). Here, we explored the prognostic value of ventricular size in LM. METHODS: We identified patients with LM from solid tumors by chart review at 3 academic hospitals to explore the prognostic associations of the EI at diagnosis, first follow-up, and progression. RESULTS: We included 113 patients...
March 12, 2024: Neurology
#13
JOURNAL ARTICLE
Daan Andel, Lotte van den Bent, Marnix Gerard Ernest Hendrik Lam, Maarten Leonard Johannes Smits, Isaac Quintus Molenaar, Joep de Bruijne, Miangela Marie Laclé, Onno Kranenburg, Inne Hildbrand Max Borel Rinkes, Jeroen Hagendoorn
BACKGROUND & AIMS: High-dose unilobar radioembolization, or 'radiation lobectomy' (RL), is an induction therapy that achieves contralateral future liver remnant hypertrophy while simultaneously irradiating the tumor. As such, it may prevent further growth, but it is unknown whether RL affects intrahepatic lymphatics, a major route via which liver tumors disseminate. METHODS: This was a case-control study conducted at University Medical Center Utrecht. The study compared lymph vessels in livers that had undergone RL (cases) with those in livers that had not undergone RL (controls)...
February 2024: JHEP reports: innovation in hepatology
#14
JOURNAL ARTICLE
Bente A van den Berge, Fatuma M A Omar, Paul M N Werker, Zhuozhao Zhan, Edwin R van den Heuvel, Dieuwke C Broekstra
BACKGROUND: Patients with Dupuytren's disease (DD) are mostly surgically treated by percutaneous needle fasciotomy (PNF) or limited fasciectomy (LF), but data on time intervals to retreatment is lacking. We aimed to estimate the risk of retreatment within certain time periods after treatment with PNF and LF. METHODS: We used data of participants of a cohort study on the course of DD who were treated only with PNF or LF. Our primary outcome measure was time to retreatment of DD...
January 30, 2024: Plastic and Reconstructive Surgery
#15
REVIEW
Nathalie L Albert, Norbert Galldiks, Benjamin M Ellingson, Martin J van den Bent, Susan M Chang, Francesco Cicone, John de Groot, Eng-Siew Koh, Ian Law, Emilie Le Rhun, Maximilian J Mair, Giuseppe Minniti, Roberta Rudà, Andrew M Scott, Susan C Short, Marion Smits, Bogdana Suchorska, Nelleke Tolboom, Tatjana Traub-Weidinger, Joerg-Christian Tonn, Antoine Verger, Michael Weller, Patrick Y Wen, Matthias Preusser
Response Assessment in Neuro-Oncology (RANO) response criteria have been established and were updated in 2023 for MRI-based response evaluation of diffuse gliomas in clinical trials. In addition, PET-based imaging with amino acid tracers is increasingly considered for disease monitoring in both clinical practice and clinical trials. So far, a standardised framework defining timepoints for baseline and follow-up investigations and response evaluation criteria for PET imaging of diffuse gliomas has not been established...
January 2024: Lancet Oncology
#16
JOURNAL ARTICLE
C Henri van Werkhoven, Anne-Wil Valk, Bente Smagge, Hester E de Melker, Mirjam J Knol, Susan Jm Hahné, Susan van den Hof, Brechje de Gier
We present early vaccine effectiveness (VE) estimates of the 2023 seasonal COVID-19 XBB.1.5 vaccine against COVID-19 hospitalisation and admission to an intensive care unit (ICU) in previously vaccinated adults ≥ 60 years in the Netherlands. We compared vaccination status of 2,050 hospitalisations including 92 ICU admissions with age group-, sex-, region- and date-specific population vaccination coverage between 9 October and 5 December 2023. VE against hospitalisation was 70.7% (95% CI: 66...
January 2024: Euro Surveillance
#17
JOURNAL ARTICLE
Philipp Karschnia, Antonio Dono, Jacob S Young, Stephanie T Juenger, Nico Teske, Levin Häni, Tommaso Sciortino, Christine Y Mau, Francesco Bruno, Luis Nunez, Ramin A Morshed, Alexander F Haddad, Michael Weller, Martin van den Bent, Niklas Thon, Juergen Beck, Shawn Hervey-Jumper, Annette M Molinaro, Nitin Tandon, Roberta Rudà, Michael A Vogelbaum, Lorenzo Bello, Oliver Schnell, Stefan J Grau, Susan M Chang, Mitchel S Berger, Yoshua Esquenazi, Joerg-Christian Tonn
No abstract text is available yet for this article.
March 4, 2024: Neuro-oncology
#18
JOURNAL ARTICLE
Emilie Le Rhun, Thierry Gorlia, Jörg Felsberg, Joost Jongen, Claude-Alain Maurage, François Ducray, Dorothee Gramatzki, Peter Hau, Olivier L Chinot, Matthias Preusser, Stephanie Cartalat, Patrick Roth, Martin van den Bent, Julia Furtner, Maike Collienne, Guido Reifenberger, Michael Weller
BACKGROUND: Zotiraciclib (TG02) is an oral multi-cyclin dependent kinase (CDK) inhibitor thought to inhibit tumor growth via CDK-9-dependent depletion of survival proteins such as c-MYC and MCL-1 which are frequently overexpressed in glioblastoma. METHODS: EORTC 1608 (NCT03224104) (STEAM) had a three parallel group (A,B,C) phase Ib, open-label, non-randomized, multicenter design in IDH wild-type newly diagnosed glioblastoma or anaplastic astrocytoma. Groups A and B explored the maximum tolerated dose (MTD) of TG02 in elderly patients, in combination with hypofractionated radiotherapy alone (group A) or temozolomide alone (group B), according to O6 -methylguanine DNA methyltransferase promoter methylation status determined centrally...
December 18, 2023: European Journal of Cancer
#19
REVIEW
Angelo Dipasquale, Chiara Barigazzi, Agnese Losurdo, Pasquale Persico, Antonio Di Muzio, Piera Navarria, Federico Pessina, Martin van den Bent, Armando Santoro, Matteo Simonelli
Historically, patients with brain metastases (BMs) have been characterized by few systemic treatment options and poor prognosis. The recent introduction of next-generation anticancer therapies such as molecular targeted agents and immunotherapy have revolutionized the clinical decision-making process of this sub-population, posing new challenges to physicians. In this review, current evidence for the use of checkpoint inhibitors and targeted therapies in patients with BMs are discussed, with a focus on lung cancer, breast cancer, melanoma and renal cell carcinoma, providing suggestions and potential workflows for daily clinical practice...
February 2024: Critical Reviews in Oncology/hematology
#20
JOURNAL ARTICLE
Tathiane M Malta, Thais S Sabedot, Natalia S Morosini, Indrani Datta, Luciano Garofano, Wies R Vallentgoed, Frederick S Varn, Kenneth Aldape, Fulvio D'Angelo, Spyridon Bakas, Jill S Barnholtz-Sloan, Hui K Gan, Mohammad Hasanain, Ann-Christin Hau, Kevin C Johnson, Simona Cazacu, Ana C deCarvalho, Mustafa Khasraw, Emre Kocakavuk, Mathilde C M Kouwenhoven, Simona Migliozzi, Simone P Niclou, Johanna M Niers, D Ryan Ormond, Sun Ha Paek, Guido Reifenberger, Peter A Sillevis Smitt, Marion Smits, Lucy F Stead, Martin J van den Bent, Erwin G Van Meir, Annemiek Walenkamp, Tobias Weiss, Michael Weller, Bart A Westerman, Bauke Ylstra, Pieter Wesseling, Anna Lasorella, Pim J French, Laila M Poisson, The Glass Consortium, Roel G W Verhaak, Antonio Iavarone, Houtan Noushmehr
Tumor adaptation or selection is thought to underlie therapy resistance in glioma. To investigate longitudinal epigenetic evolution of gliomas in response to therapeutic pressure, we performed an epigenomic analysis of 132 matched initial and recurrent tumors from patients with IDH-wildtype (IDHwt) and IDH-mutant (IDHmut) glioma. IDHwt gliomas showed a stable epigenome over time with relatively low levels of global methylation. The epigenome of IDHmut gliomas showed initial high levels of genome-wide DNA methylation that was progressively reduced to levels similar to those of IDHwt tumors...
December 20, 2023: Cancer Research
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
